Drug Trial Radar · NCT02141139
Perioperative Inflammation and Breast Cancer Outcome
Last checked: Nov 19, 2026Latest source record: May 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,568
Planned (sponsor's estimate)
Start
Sep 2014
Primary completion
Jan 2016
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.
Conditions
- Breast Neoplasms
Interventions
NSAIDS (ketorolac and ibuprofen)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- disease free survivalTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.